Ascletis Pharma Inc. disclosed in its Next Day Return (11 June 2026) that it repurchased 200,000 ordinary shares on the Hong Kong Stock Exchange the same day. The shares were bought within a price range of HKD 9.63–10.11, translating into an average cost of HKD 9.83 per share and an aggregate consideration of HKD 1.97 million.

The repurchased stock will be cancelled, leaving the company’s share capital structure unchanged ahead of formal cancellation: • Issued shares (excluding treasury shares) remain at 1,061,370,845. • Treasury shares stand at 7,084,210, keeping total issued shares at 1,068,455,055.

Buy-back mandate utilisation • Ascletis received shareholder approval on 22 May 2025 to repurchase up to 96.28 million shares. • Including the latest transaction, 7.89 million shares have been bought back, equal to 0.82 % of the issued share base on the mandate date.

Regulatory timeline Under Hong Kong Listing Rule 10.06(3), the company is subject to a moratorium on issuing new shares or selling treasury shares until 11 July 2026—30 days after the most recent repurchase.

The company confirmed all repurchases were executed in compliance with Hong Kong Stock Exchange requirements and that no changes have been made to the explanatory statement lodged on 29 April 2025.